Interim recommendations for heterologous COVID-19 vaccine schedules
Interim guidance
16 December 2021
| COVID-19: Vaccines
Overview
This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
For translations in other WHO languages click here.
WHO Team
Agenda, Policy & Strategy (APS),
Immunization, Vaccines and Biologicals (IVB),
Strategic Advisory Group of Experts on Immunization,
WHO Headquarters (HQ)
Number of pages
18
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/heterologous_schedules/2021.1
Copyright
